PT - JOURNAL ARTICLE AU - Ghosh, Debojoyti AU - Panja, Amrita AU - Saha, Dipankar AU - Banerjee, Uma AU - Dutta, Asok Kumar AU - Basu, Anupam TI - Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphism AID - 10.1101/2021.02.28.21251843 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.28.21251843 4099 - http://medrxiv.org/content/early/2021/03/01/2021.02.28.21251843.short 4100 - http://medrxiv.org/content/early/2021/03/01/2021.02.28.21251843.full AB - Aims HbE/β-thalassemia is the prevalent form of severe β-thalassemia in Asian countries. Hydroxyurea (HU) is the most common drug used for the management of sickle-cell anemia but not thalassemia. Here, we aimed to assess clinical HU response among patients with HbE/β-thalassemia with respect to Xmn1 γGglobin polymorphism and elucidate the association between this polymorphism and HU response efficacy.Methods We enrolled 49 transfusion-dependent patients with HbE/β-thalassemia. Fetal hemoglobin level was measured using High-performance liquid chromatography (HPLC) and complete blood count was determined pre- and post-HU therapy. Polymerase chain reaction–Restriction fragment length polymorphism (PCR-RFLP) was performed for genotyping Xmn1 γGglobin polymorphism.Results A total of 30 (61.22%) patients were found to be responders, whereas the remaining 19 (38.78%) were non-responders. We found 33 patients with heterozygous (C/T) and three with homozygous mutant (T/T) genotype status. We obtained a statistically significant correlation (p < 0.001) between Xmn1 polymorphism and transfusion-free interval. Patients with Xmn1 polymorphism were found to be good responders for HU therapy and showed increased hemoglobin levels.Conclusions Our findings indicate that HU is a potential drug candidate for thalassemia management, particularly HbE/β-thalassemia. The results hold implications in repurposing HU as an effective and efficient therapy for HbE/β-thalassemia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the Council of Scientific & Industrial Research (CSIR) (fellowship to AP, Award no. F.NO.09/025(0196)/2011-EMR-I), Fund for Improvement of S&T Infrastructure (FIST) program of Department of Science & Technology (DST-FIST) (infrastructural facility), and the Department of Science and Technology, Government of West Bengal (grant number: 687(Sanc.)/ST/P/S and amp;T/1G-20/2014, to AB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Ethics Committee of Burdwan Medical College and conducted in compliance with the Declaration of Helsinki. Written informed consent and assent forms were collected from the parents/guardians of all the participants prior to enlistment in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be obtained on request